Company intelligence / Profile preview
Beijing Luzhu Biotechnology
Beijing, Beijing, Chinaluzhubiotech.com ↗
- Ownership
- Private
- Employees
- ~148
- Development stage
- Other
01
Overview
LZ901, a recombinant herpes zoster vaccine candidate, has completed Phase II clinical trials in China with positive immunogenicity and safety results. A multi-center Phase III trial is underway. The company’s adalimumab biosimilar candidate K3 is expected to enter/completed Phase III in China by late 2024. The bispecific antibody K193 for B cell malignancies is advancing through early clinical stages. Four additional preclinical candidates are under development.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- VaccineMonoclonal antibodyBispecific monoclonal antibodyRecombinant protein
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Partnerships
No major disclosed pharma partnerships; focus on internal R&D and outlicensing strategy
Beyond the preview
Go deeper on Beijing Luzhu Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beijing Luzhu Biotechnology.